Weight Management

Editorial note: TotalCareMedical.com is an independent health and wellness research publication. We are not a medical practice and do not provide medical advice. This article compares two compounded GLP-1 telehealth platforms — Refills and SynergyRx — on the dimensions that matter for consumer evaluation. Compounded GLP-1 medications dispensed through either platform are not FDA-approved finished drug products. The FDA has not evaluated these compounded medications for safety, quality, or efficacy. Anyone considering GLP-1 therapy should consult a qualified healthcare provider about individual eligibility, contraindications, and risks. Individual results vary.

Refills and SynergyRx are two of the more visible compounded GLP-1 telehealth platforms operating in the United States right now. Both market direct-to-consumer access to compounded semaglutide and tirzepatide along with brand-name FDA-approved options. Both use the now-standard three-entity structure: technology platform, partner clinician network, dispensing pharmacy partners. Both target a similar consumer profile.

The platforms are not identical, though. Pricing structure differs meaningfully. Pharmacy partnerships are different. Clinician network is different. Promotional offer structure is different. This piece walks through the head-to-head comparison on the dimensions that matter for the consumer's actual decision: pricing, medication access, transparency, structural disclosure, and the fit-to-scenario matchup.

Corporate Structure and Disclosure

Both platforms are technology companies that connect consumers with independent licensed clinicians and dispensing pharmacy partners. Neither is a medical practice. Neither directly prescribes or dispenses medication. Both state this clearly in their terms.

Refills Health LLC is incorporated in Delaware and headquartered in Wilmington. The platform was founded in April 2025 with Matt Osborn as CEO. Refills' clinician network operates through Beluga Health, Bask Health, and Wasef Health. The dispensing pharmacy partner currently identified in Refills' terms is Perfect Rx Pharmacy in Texas, with a note that additional partners may be added.

SynergyRx operates a similar structure. Its clinician network operates through Lion MD, with named medical directors Dr. Ana Lisa Carr MD and Dr. Kelly Tenbrink MD providing leadership. SynergyRx's pharmacy partnerships are broader than Refills' currently disclosed partnership: SynergyRx names Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, and Casa Pharma Rx as dispensing partners.

The structural disclosure read: both platforms operate above the category transparency average. Both name their clinician partner organization. Both disclose at least one dispensing pharmacy. SynergyRx's broader pharmacy network is the more diversified disclosure on the dispensing side. Refills' clinician network spans three named medical groups (Beluga, Bask, Wasef), which is more breadth on the clinician side.

Pricing — Where the Two Platforms Diverge Most

The pricing structures are different in ways that meaningfully affect consumer scenarios. The full Refills GLP-1 pricing breakdown covers the Refills tiers in detail; the short version is that Refills offers a $159 first-month promo, a $399 standard recurring rate, and a $6/day annual plan that averages roughly $180 per month when paid up front for 12 months.

SynergyRx's pricing is structured more as a flat tier. Compounded semaglutide injection starts at $199. Compounded tirzepatide injection starts at $349. Compounded oral options are listed at $299 (semaglutide) and $399 (tirzepatide). Brand-name options price higher: Wegovy and Mounjaro start at $947, Ozempic starts at $499. SynergyRx's pricing structure is less promo-heavy; the consumer sees the recurring rate from the start.

The pricing comparison on compounded semaglutide injection — the headline product on both platforms:

Refills: $159 first month (promotional), then $399 monthly standard or roughly $180/month equivalent on the 12-month annual plan.

SynergyRx: Starting at $199 per month with no documented promotional first-month rate.

What that means in practice: the cheapest first-month entry on Refills ($159) is more aggressive than the cheapest first-month entry on SynergyRx ($199). The cheapest ongoing month-to-month rate on Refills ($180 equivalent on annual plan) is comparable to the SynergyRx starting rate ($199). The non-annual recurring rate on Refills ($399) is meaningfully higher than the SynergyRx starting rate. The consumer who wants the lowest possible long-term cost without an annual commitment may find SynergyRx structurally better. The consumer who wants the lowest possible first-month entry to test the platform may find Refills structurally better. The consumer who is committed to annual prepayment finds the two platforms close on long-term cost.

Medication Options Available

Both platforms list both compounded and brand-name GLP-1 options. The breadth of medication options is broadly similar.

Refills lists access to compounded Personalized GLP-1 (compounded semaglutide injection) and brand-name Ozempic, Wegovy, Zepbound, and Saxenda. Refills also operates outside the GLP-1 weight management category, with offerings in better intimacy (sildenafil, tadalafil, Viagra, Cialis), daily health (NAD+, sermorelin, methylene blue), and hair growth (oral finasteride, oral minoxidil, finasteride-and-minoxidil topical spray). For the GLP-1-specific consumer, the cross-category breadth is not directly relevant; for a consumer interested in multiple categories from one platform, Refills' broader catalog is meaningful.

SynergyRx lists access to compounded semaglutide (injection and oral dissolving tablet), compounded tirzepatide (injection and oral dissolving tablet), and brand-name Ozempic, Wegovy, and Mounjaro. SynergyRx is more focused on weight management than Refills, with less cross-category catalog. The oral compounded options (semaglutide and tirzepatide oral dissolving tablets) are more prominently positioned on SynergyRx; Refills' compounded option is positioned as injection.

For a consumer specifically interested in oral compounded GLP-1, SynergyRx is the more direct fit. For a consumer specifically interested in injectable compounded GLP-1, both platforms compete directly. For a consumer interested in tirzepatide specifically, both platforms list it; SynergyRx's pricing on compounded tirzepatide ($349 starting for injection) is documented more prominently than Refills'.

Clinician Network and Intake Process

Both platforms route intake through licensed clinicians. Both states the clinician makes the prescribing decision; the platform does not. Both follow established medical protocols for GLP-1 prescribing eligibility — typically BMI 30 or higher, or 27 or higher with a qualifying weight-related condition.

The intake process is broadly similar across both: medical history, current medications, allergies, weight history, treatment goals, contraindication screening (including MTC and MEN 2 history, pancreatitis history, and other clinically relevant items). The structural intake quality is comparable.

SynergyRx names its medical directors specifically — Dr. Ana Lisa Carr MD (NPI: 1689841744) and Dr. Kelly Tenbrink MD (NPI: 1346482684) — which is a level of specific named-clinician disclosure that is unusual in the category. Refills names its clinician partner organizations (Beluga, Bask, Wasef) without naming individual medical directors at the platform level. SynergyRx's specific NPI-level disclosure is the more granular transparency on the clinician side.

Pharmacy Network and Fulfillment

SynergyRx's broader pharmacy network — four named partners (Belmar, Strive, Epiq Scripts, Casa Pharma Rx) — provides more redundancy and potentially more flexibility on fulfillment than Refills' current single-partner disclosure (Perfect Rx Pharmacy in Texas, with a note that more may be added). Diversified pharmacy networks reduce single-point-of-failure risk if any one pharmacy experiences supply issues, regulatory action, or operational problems.

Both platforms allow patients to direct prescriptions to a pharmacy of their choosing under their respective terms. The platform price covers in-network fulfillment only; out-of-network pharmacies are paid directly by the patient.

Both platforms reference shipping that is included in the program price. Refills documents three-to-five-day standard shipping with overnight shipping referenced on some pages. SynergyRx documents shipping included in the price without specific timing disclosure.

The FDA Compounded Disclaimer on Both Platforms

Both platforms display the standard regulatory disclaimer: compounded medications dispensed are not FDA-approved finished drug products and have not been evaluated by the FDA for safety, quality, or efficacy. The disclaimer language is materially equivalent on both platforms. Both platforms identify their dispensing pharmacy partners as licensed and inspected by State Boards of Pharmacy.

The structural compounded medication context — what the disclaimer means in practice and how the regulatory framework actually works — is covered in our editorial explainer on how compounded semaglutide telehealth works. The substantive read on either platform is the same: the consumer is buying a state-regulated preparation of a well-studied active molecule, prescribed by a licensed clinician, but not the same finished product the FDA reviewed. That regulatory context applies equally to both platforms.

Cancellation and Consumer Protection

Both platforms operate on subscription models with online cancellation through the user dashboard. Both follow the standard regulatory rule that prescription medications cannot be returned once dispensed.

Refills' specific window: the consumer can cancel before the prescription is sent to the pharmacy, after which the order's payment is final. SynergyRx operates a comparable window with similar mechanics. Neither platform's cancellation flexibility is materially different from the other on standard month-to-month plans.

Annual plan refund mechanics on both platforms are subject to how much medication has already been dispensed. Refills' $6/day annual plan and any equivalent SynergyRx multi-month commitment carry similar refund constraints once medication has been routed to the pharmacy.

Which Platform Fits Which Consumer Scenario

The clearest fit-to-scenario reading from the head-to-head comparison:

Refills fits the consumer testing GLP-1 access at low first-month commitment. The $159 promo is the most aggressive entry rate on the comparison. For someone uncertain whether they'll continue past month one, the lower entry cost reduces financial exposure during the trial period. Refills also fits the consumer who is highly confident in long-term commitment and willing to commit to or finance the annual plan, since the annual rate averages near the lowest sustained rate available.

SynergyRx fits the consumer wanting consistent month-to-month pricing without an annual commitment. The $199 starting rate without a promo step-up is more predictable across the first six to twelve months than Refills' $159-to-$399 transition. SynergyRx also fits the consumer specifically interested in compounded oral dissolving tablet options, which are more prominently positioned in SynergyRx's product line.

Either platform fits the consumer who wants both compounded and brand-name access. Both list brand-name Ozempic, Wegovy, and Mounjaro at broadly comparable pricing.

Neither platform fits the consumer with complex medical history requiring extensive coordinated care. Direct-to-consumer compounded GLP-1 telehealth is structurally suited for healthier patients seeking convenient access to a specific therapy. Patients with significant comorbidities, complex medication interactions, or insurance-covered GLP-1 access are typically better served by traditional in-person care or insurance-routed treatment paths. Our piece on Refills GLP-1 side effects and safety covers the contraindications and clinical scenarios where telehealth platforms generally are not the optimal fit.

The Honest Editorial Takeaway

Refills and SynergyRx are both competent compounded GLP-1 telehealth platforms operating with above-average structural transparency for the category. Neither is markedly worse than the other on any dimension. The differences live in pricing structure, pharmacy network breadth, and clinician disclosure specifics — not in fundamental quality of the offering.

The right choice for any individual depends on which structural feature matters most to that consumer. Lowest first-month entry: Refills. Most consistent ongoing month-to-month rate without annual commitment: SynergyRx. Broadest dispensing pharmacy network: SynergyRx. Most named-clinician disclosure: SynergyRx (NPI-level). Broadest cross-category catalog beyond GLP-1: Refills. Lowest sustained rate with annual commitment: Refills (slight edge).

For the full per-platform editorial reads, see our Refills GLP-1 review and the SynergyRx GLP-1 review. Broader category context lives at our Telehealth Platform Reviews hub, with adjacent weight management coverage at the Weight Management hub.

Whichever platform fits the individual consumer's specific scenario, the underlying clinical decision — whether GLP-1 therapy is appropriate at all — is a conversation between that consumer and a licensed healthcare provider. The platforms are delivery mechanisms. The clinical relationship is what makes treatment work.

Editorial note: TotalCareMedical.com is an independent health and wellness research publication. We are not a medical practice and do not provide medical advice. This article is an educational overview of known GLP-1 receptor agonist side effects and safety considerations, drawing on published clinical trial data and FDA-approved prescribing information for brand-name GLP-1 medications. Compounded GLP-1 medications dispensed through Refills are not FDA-approved finished drug products. The FDA has not evaluated these compounded medications for safety, quality, or efficacy. Anyone considering GLP-1 therapy should consult a qualified healthcare provider about individual eligibility, contraindications, and risks. This is not medical advice. Individual results vary.

The safety conversation around GLP-1 medications has two layers, and conflating them produces confused consumer reading. The first layer is the side-effect profile of the active molecule itself — semaglutide, tirzepatide — which is well-documented in peer-reviewed clinical trials and in FDA-approved prescribing information for brand-name finished products. The second layer is the regulatory framework around compounded preparations specifically, which is a different conversation about how the medication is prepared and what oversight applies to that preparation.

This article addresses both layers honestly. What the trial data and prescribing information show about how GLP-1 medications act in patients. What contraindications matter. What the FDA compounded disclaimer actually says about safety. And what the patient should be ready to discuss with the evaluating clinician at intake on the Refills GLP-1 program — or any other compounded GLP-1 telehealth platform — to make the clinical evaluation as effective as it can be.

The Side-Effect Profile of GLP-1 Receptor Agonists

The most commonly reported side effects of GLP-1 receptor agonists in clinical trials are gastrointestinal. The mechanism explains the pattern: GLP-1 agonists slow gastric emptying and act on appetite regulation centers, which produces appetite suppression and a feeling of fullness — and which also produces nausea, vomiting, diarrhea, constipation, and abdominal discomfort in a meaningful percentage of patients, especially during early treatment and during dose escalation.

In the STEP-1 trial of semaglutide 2.4 mg published in the New England Journal of Medicine, gastrointestinal side effects were the most commonly reported adverse events. Nausea was reported in roughly 44 percent of participants in the medication arm at some point during the trial. Diarrhea was reported in roughly 32 percent. Constipation in roughly 24 percent. Vomiting in roughly 24 percent. The placebo arm reported all of these symptoms at lower rates, but the symptoms were not absent in the placebo arm — the difference between medication and placebo gives the attributable side-effect picture.

For tirzepatide in the SURMOUNT-1 trial, the gastrointestinal pattern was similar. Nausea was the most commonly reported adverse event. Diarrhea, constipation, and vomiting all appeared at clinically relevant rates. The pattern across the GLP-1 class is consistent: GI effects are the dominant side-effect profile, they tend to be most pronounced during dose escalation, and they tend to attenuate as the body adjusts to a stable dose.

Severity of GI effects varies substantially across patients. Some report mild, transient nausea that resolves within days. Some report more persistent symptoms that take weeks to attenuate. Some report severe enough symptoms that they discontinue therapy. Anyone starting GLP-1 should expect some level of GI adjustment and should have a clear plan with the evaluating clinician for what symptom severity warrants slowing dose escalation, pausing therapy, or contacting the care team.

Less Common but More Serious Risks

Beyond the common GI side-effect profile, GLP-1 prescribing information documents less common but more serious potential risks. These are not features of typical treatment — they are documented possibilities that merit clinical awareness and prompt evaluation if symptoms develop.

Pancreatitis has been reported in association with GLP-1 receptor agonist therapy in post-marketing surveillance and in some clinical observations. The clinical signature is severe abdominal pain, often radiating to the back, frequently with persistent nausea and vomiting beyond what would be expected from typical GI side effects. Patients should be aware of the symptom pattern and should contact a clinician promptly if symptoms consistent with pancreatitis develop. History of pancreatitis is a significant clinical consideration that the evaluating clinician must weigh.

Gallbladder disease — including gallstones and cholecystitis — has been associated with rapid weight loss generally and with GLP-1 therapy specifically. Patients losing weight rapidly are at increased risk of gallstone formation, and GLP-1 therapy can potentiate that risk. Clinical signs include right-upper-quadrant abdominal pain, often after eating fatty meals, and may require imaging and surgical evaluation.

Acute kidney injury has been reported, often in the context of severe dehydration from prolonged vomiting and reduced fluid intake. Maintaining hydration during GLP-1 therapy is clinically important, particularly during dose escalation periods when GI symptoms are most pronounced.

Severe hypoglycemia is a particular consideration for patients also taking insulin or sulfonylureas. GLP-1 alone has a low risk of hypoglycemia in patients without these other agents, but combined with insulin or insulin secretagogues, the risk increases meaningfully and requires clinical adjustment of the other medications.

Allergic reactions, including rare but potentially serious reactions, have been reported. Any sign of allergic reaction — particularly facial swelling, difficulty breathing, or severe rash — warrants immediate medical attention.

Contraindications That Matter

The most clinically significant contraindication for GLP-1 receptor agonists in widespread use is a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The boxed warning in FDA-approved GLP-1 prescribing information is built around this contraindication. The mechanism that drove the warning involves rodent thyroid C-cell tumor findings in preclinical studies; the human clinical relevance is debated but the contraindication is firm in current prescribing.

Patients with a personal or family history of MTC or MEN 2 should not take GLP-1 receptor agonists. This is not a “discuss with your doctor” recommendation; it is a contraindication. Any thoroughgoing intake on a compounded GLP-1 telehealth platform — Refills included — should explicitly screen for MTC and MEN 2 history. If the intake does not screen for this, that is a meaningful red flag about the platform's clinical seriousness.

History of pancreatitis is a significant clinical consideration. Severe gastrointestinal disease, gastroparesis, and certain other GI conditions may also affect candidacy. Pregnancy and lactation are typically considered contraindications or relative contraindications depending on the specific clinical scenario. Severe renal or hepatic impairment may affect dosing or candidacy. The evaluating clinician integrates all of these factors based on the full intake.

For broader weight management context, evidence-based natural strategies covered in our research on natural weight management timelines may serve as a starting point for patients who are not appropriate candidates for pharmacological therapy. Pharmacological intervention is one tool among many, and clinical appropriateness varies.

What the FDA Compounded Disclaimer Actually Means for Safety

Refills states this directly on its website: compounded medications are dispensed by U.S. pharmacies that are highly regulated and inspected by State Boards of Pharmacy, but the FDA has not evaluated these compounded medications for safety, quality, or efficacy. That language is not a footnote and not a formality. It deserves an honest reading.

What it means: the FDA has not run its own review on this specific compounded preparation as a finished product. The agency reviews finished branded drugs through processes like the New Drug Application and ongoing post-marketing surveillance. Compounded preparations made at 503A pharmacies are not subject to those same processes. Compounded preparations made at 503B outsourcing facilities are subject to additional FDA oversight including current Good Manufacturing Practice requirements, but still are not FDA-approved as finished drugs.

What it does not mean: that the medication is unsafe, that the compounding pharmacy is unregulated, or that the active molecule lacks clinical evidence. State Boards of Pharmacy regulate compounding pharmacies including inspections and quality controls. The active molecule (semaglutide, tirzepatide) has substantial peer-reviewed clinical research behind it. Many compounded medications are dispensed safely under appropriate clinical oversight every day.

The honest patient-safety reading: the consumer is buying a state-regulated preparation of a well-studied active molecule, prescribed by a licensed clinician, but not the same finished product the FDA reviewed. The clinician's evaluation, the dispensing pharmacy's quality controls, and ongoing patient monitoring are the safety infrastructure that surrounds any compounded GLP-1 prescription. We cover the structural details of how that infrastructure works in our explainer on compounded semaglutide telehealth.

What to Disclose on Intake

Full disclosure on the intake form supports clinical safety. Items that matter and should be disclosed completely include: full medical history including any chronic conditions; all current prescription medications, over-the-counter medications, and supplements; all known allergies; history of thyroid disease or thyroid cancer in the patient; family history of medullary thyroid carcinoma or MEN 2 syndrome; history of pancreatitis; history of gallbladder disease; history of eating disorders; current pregnancy status or plans for pregnancy; chronic gastrointestinal conditions; history of severe diabetic complications including gastroparesis or proliferative diabetic retinopathy; and any other symptom or condition that might affect medication metabolism or tolerability.

Incomplete disclosure undermines the clinician's ability to evaluate whether GLP-1 therapy is appropriate. The intake is not a sales-funnel form to push through quickly; it is the clinical document the prescriber works from. Treating it accordingly is in the patient's own safety interest.

Monitoring During Treatment

GLP-1 therapy is not a “set and forget” medication. The standard clinical model includes ongoing monitoring during dose escalation and during stable maintenance. Refills' standard program structure includes follow-ups, unlimited clinician access, and required blood work as part of the monthly tier — which is the appropriate monitoring infrastructure for the medication class.

What ongoing monitoring should reasonably cover: tolerance to the current dose, symptom monitoring for any of the more serious risks above, weight and metabolic markers, hydration status, and dose adjustment based on response. The patient's role in monitoring is to report symptoms accurately, follow the dose schedule, maintain hydration, and contact the care team for any symptom that feels unusual or concerning rather than waiting for the next scheduled check-in.

When to Contact a Clinician — and When to Skip Telehealth and Go to the ER

Telehealth messaging is appropriate for non-urgent symptom questions, dose adjustment discussions, and routine monitoring conversations. The Refills platform provides messaging access to the care team for these purposes. The expected response window is documented in the platform terms.

Telehealth is not appropriate for emergent symptoms. Severe abdominal pain especially radiating to the back, signs of severe allergic reaction, signs of severe dehydration with confusion or extreme weakness, severe persistent vomiting, signs of acute hypoglycemia in a patient on insulin, or any other symptom that feels acutely serious should prompt immediate contact with local emergency services or an emergency department rather than waiting for telehealth response.

The honest framing: the telehealth platform is one piece of the patient's safety infrastructure, not the entirety of it. Local emergency care exists for emergencies. Using it appropriately when symptoms are acutely serious is the correct safety behavior.

Who Should Talk to a Different Provider Instead

Some clinical scenarios are better served by traditional in-person care than by any telehealth platform. Patients with complex multi-system medical histories, patients with significant prior GI conditions, patients with diabetes that is poorly controlled or that requires complex insulin management, and patients on multiple chronic medications with known interactions often benefit from in-person evaluation with a primary care physician or endocrinologist who can coordinate the full medication picture.

The convenience of telehealth is real; the limitations are also real. A platform like Refills is structurally well-suited for healthier patients seeking convenient access to a specific therapy. It is structurally less well-suited for patients whose situation requires extensive coordination across providers and systems.

For broader context on the program structure and pricing, see our full Refills GLP-1 review and the Refills GLP-1 pricing breakdown. The category context lives at our Telehealth Platform Reviews hub.

The Final Safety Reading

GLP-1 receptor agonists are evidence-based pharmacological treatments for the patients they're appropriate for. The side-effect profile is well-documented and predominantly gastrointestinal. The serious risks are uncommon but real and warrant clinical awareness and prompt symptom evaluation. The contraindications — particularly MTC and MEN 2 history — are firm and matter.

The compounded preparation regulatory framework is a separate question from the active molecule's pharmacological profile. The FDA disclaimer is substantive but not a verdict that the medication is unsafe. The clinician's evaluation, the dispensing pharmacy's regulation, and ongoing monitoring constitute the safety infrastructure around any compounded GLP-1 prescription.

The honest patient takeaway: GLP-1 therapy can be a meaningful tool for the patients it's right for. Determining whether it's right for any individual patient is a clinical conversation, not a marketing decision. Disclose fully on intake, ask the clinician explicit questions about contraindications relevant to your history, agree on a clear monitoring plan, and use the care team appropriately during treatment. The platform is the delivery mechanism; the clinical relationship is the safety infrastructure. Both have to function for the treatment to function safely.

Editorial note: TotalCareMedical.com is an independent health and wellness research publication. We are not a medical practice and do not provide medical advice. This article walks through the pricing structure of the Refills GLP-1 program based on information published on refills.com and across Refills' marketing pages as of mid-2026. Pricing is subject to change at any time and should be verified at refills.com before any purchase decision. Compounded GLP-1 medications dispensed through Refills are not FDA-approved finished drug products. The FDA has not evaluated these compounded medications for safety, quality, or efficacy.

Refills' GLP-1 pricing is more layered than the most prominent landing-page number suggests. The $159 first-month promo is real, but it's the entry rate, not the recurring rate. The $399 standard monthly is real and lives on Refills' own program page, but it's not the only path forward — there's a $6/day annual plan that averages roughly $180 per month if paid up front. Each tier serves a different consumer profile, and the right one for any individual depends on how committed they already are to ongoing GLP-1 therapy and what their cash flow looks like.

This piece breaks the math down honestly. What each tier costs, what each includes, what's bundled and what isn't, how the annual plan financing actually works, and which tier fits which consumer scenario. We're working only from numbers Refills publishes on its own site and from confirmed pricing reporting; nothing here is fabricated, and nothing here softens the standard rate to make the promotional rate look better.

The Promotional Rate: $159 for the First Month

Refills' most prominent marketing offer is a $159 first-month rate. The number appears on multiple Refills landing pages and is one of the most aggressive promotional entry points in the compounded GLP-1 telehealth category. At $159, Refills is competing on price for the consumer who is curious about GLP-1 access but not yet committed to ongoing therapy.

The promotional rate covers the same first-month deliverables the standard rate covers: clinician review of the intake, prescription if approved, a four-week medication supply, and shipping. Refills also markets “all dosages at the same low price” and “free overnight shipping” alongside the promo, plus the ability to cancel online at any time and no membership fees beyond the medication subscription.

The promotional rate is not the rate at which the relationship continues. After month one, the subscription transitions to whichever recurring tier the consumer selected at sign-up. That transition is where the budgeting reality of the program gets clearer.

The Standard Recurring Rate: $399 per Month

Refills' official program landing page lists the standard monthly rate at $399. This rate is documented on Refills' own materials and is the recurring number the consumer should plan around if they are signing up without committing to the annual plan.

What the $399 monthly tier includes, per Refills' own program page: physician evaluations, follow-ups, unlimited clinician access, monthly prescriptions, a four-week medication supply, any required blood work, and shipping. Refills also notes that the same flat rate applies regardless of dosage adjustments — the patient is not charged more if their clinician titrates them up to a higher dose.

That last point matters. Some telehealth platforms tier their pricing by dose, charging more as the patient escalates. The Refills flat-rate model is consumer-favorable in this respect, because GLP-1 dose titration upward is a clinically standard part of therapy and the patient is not penalized financially for following the protocol. Whether the flat rate is the best value depends on what the alternatives charge for equivalent dose levels.

The Annual Plan: $6/Day, Roughly $180/Month Averaged

Refills also markets pricing “as low as $6 per day” available on a 12-month commitment, paid either fully up front or financed through a buy-now-pay-later partner. At $6 per day, the annual plan averages approximately $180 per month across the 12 months — substantially below the $399 standard rate, and roughly comparable to the $159 promotional first month spread across the year.

The math: $6 × 365 days = $2,190 per year. Divided by 12 months, that's $182.50 per month equivalent. The exact monthly figure shifts depending on the specific annual offer terms, financing fees if any, and whether Refills changes the program details across the year. The order of magnitude is consistent: the annual plan prices ongoing therapy at roughly half the standard monthly rate.

The trade-off is straightforward. The patient commits to (or finances) 12 months up front. If GLP-1 therapy turns out to not be appropriate after the clinician evaluation, refund mechanics apply. If the patient decides midway through the year that they want to discontinue, the prepaid amount is generally not refundable for medication that has already been dispensed under state and federal regulations on prescription returns. The annual plan is structurally for the consumer who has either already had a positive experience with GLP-1 therapy or is highly confident based on clinical conversation that they want to commit to ongoing use.

Brand-Name Medication Pricing — A Different Tier Entirely

Refills' lower-priced tiers ($159, $180, $399) are for the compounded GLP-1 options — primarily the Personalized GLP-1 (compounded semaglutide injection). Refills also lists access to brand-name FDA-approved medications: Ozempic, Wegovy, Zepbound, and Saxenda.

Brand-name GLP-1 prescriptions through telehealth typically cost substantially more than compounded options. Across the category, brand-name Ozempic telehealth pricing commonly starts around $499 per month, with Wegovy and Mounjaro often listed at $947 or higher. Refills' specific brand-name pricing is not as prominently published as its compounded pricing and should be verified at intake. The structural pattern across the industry, though, is clear: brand-name medications cost two to four times what compounded medications cost when paid out of pocket through telehealth.

The math becomes very different if the consumer has insurance coverage for GLP-1 medications. Most direct-to-consumer telehealth platforms — Refills included — do not bill insurance, which means the cash price is the actual cost. A patient with employer insurance that covers Wegovy with a moderate copay will often find the insurance-routed brand-name path cheaper than the cash compounded path. A patient without coverage finds the compounded path dramatically cheaper than the cash brand path.

What Is Not Bundled into the Monthly Price

The Refills monthly price covers the program elements listed above. A few categories of cost can fall outside the bundled price depending on individual circumstances. Lab work that goes beyond what's standard for the program (for example, additional testing if the clinician identifies a need based on intake) may incur additional cost in some scenarios. If the patient elects to direct their prescription to a pharmacy outside Refills' in-network pharmacy partner, that out-of-network pharmacy is paid directly by the patient, separately from the Refills platform price.

Shipping is included on the standard offer. Promotional pages reference free overnight shipping in some contexts and three-to-five-day shipping in others, which the consumer should clarify at checkout depending on which offer they're entering through. Returns of dispensed prescription medications are not legally permitted under state and federal regulations regardless of the platform's individual policies.

Cancellation Mechanics — When and How

Refills states that subscribers can cancel online at any time through their account dashboard. The window for cancellation that prevents a charge is the period between order placement and the prescription being routed to the dispensing pharmacy. Once the medication has been dispensed and shipped, that order's payment is final per state and federal regulations on prescription medications.

For a standard monthly subscription, this means the consumer can cancel before their next month's prescription is processed and avoid the next month's charge. For the annual plan paid up front, the structural commitment is different — the consumer has already paid for 12 months of medication, and refund mechanics for prepaid annual programs vary depending on how much medication has already been dispensed.

The honest budgeting reading: the standard monthly subscription has good consumer flexibility on cancellation. The annual plan trades flexibility for lower per-month cost. Neither is wrong; they fit different scenarios.

How Refills Pricing Compares to the Category

The compounded GLP-1 telehealth category has a wide pricing range. Some platforms market promotional first months as low as $99. Standard recurring rates across competitors range from roughly $200 to $400 per month. Annual or quarterly prepayment options are common across most major platforms. SynergyRx, for example, lists compounded semaglutide injection starting at $199 and compounded tirzepatide starting at $349, with brand-name options priced higher. Our companion piece on Refills vs SynergyRx walks through the head-to-head comparison in detail.

Refills' $159 first-month promo is at the aggressive end of the category. The $399 standard rate is at the higher end. The annual plan averaging $180 per month is in line with mid-tier annual options across competitors. The pricing structure is competitive but not necessarily the absolute lowest — what Refills competes on is the structural transparency of how the layers (platform, clinician, pharmacy) are disclosed, the ease of the intake-to-delivery process, and the consistency of the flat dosage pricing across titrations.

Which Tier Fits Which Consumer

The $159 first-month promo is for the consumer testing GLP-1 access. They want to see the intake process, get a clinician evaluation, see how the medication delivery works, and then decide whether ongoing therapy fits their situation. Low first-month commitment, full ability to cancel before month two, and a clinical evaluation included.

The $399 standard monthly fits the consumer who is settled on GLP-1 therapy but wants flexibility — they don't want to commit to a year up front, perhaps because they're uncertain about long-term cost or want to maintain optionality if their situation changes. Higher per-month cost, but no annual commitment.

The $6/day annual plan fits the consumer who is highly confident GLP-1 therapy is right for them — perhaps based on a positive clinical conversation, a prior trial of GLP-1, or strong personal commitment to a 12+ month protocol. Substantially lower per-month cost, but the trade-off is upfront commitment or financing.

None of these tiers is universally better. The honest match depends on the consumer's clinical situation, financial situation, and risk tolerance for long-term commitment. The full editorial review of the Refills program — covering structure, compliance, and clinical context as well as pricing — lives at our Refills GLP-1 review. The safety profile of GLP-1 therapy itself, including contraindications and common side effects, is at Refills GLP-1 side effects and safety.

Broader telehealth weight management context — including alternative platforms and natural strategies — is at our Telehealth Platform Reviews hub and the Weight Management hub.

Final Pricing Reality Check

The honest answer to “what does Refills cost” is: it depends on which offer the consumer enters through and which plan they select. The first month is $159 promotional. Ongoing month-to-month is $399 standard. Annual prepayment averages roughly $180 per month. All three numbers are documented on Refills' own pages, and Refills does not hide the standard rate.

What the consumer should do at intake: confirm exactly which plan they're enrolling in, when the promotional rate transitions to the recurring rate, what the recurring rate is for their specific plan, what the cancellation mechanics are for that plan, and whether shipping and clinician access remain bundled at the recurring rate. Pricing is subject to change at any time. Always verify current costs and program details directly on the official Refills website before making a purchase decision.

Editorial note: TotalCareMedical.com is an independent health and wellness research publication. We are not a medical practice and do not provide medical advice. This article explains how compounded semaglutide telehealth platforms operate as a category. Compounded GLP-1 medications are not FDA-approved finished drug products. The FDA has not evaluated these compounded preparations for safety, quality, or efficacy. Anyone considering prescription GLP-1 therapy should consult a qualified healthcare provider about eligibility and individual risks.

Search results for “compounded semaglutide” return a mix of telehealth landing pages, regulatory news, and consumer warnings — and the layperson reading them comes away with a fragmented picture of how the category actually works. Three separate entities are involved in any compounded GLP-1 telehealth purchase, each does a specific thing, and understanding the structure makes the rest of the consumer evaluation much clearer. This piece walks through the platform, the prescriber, and the pharmacy — what each does, what each is regulated by, and what the FDA disclaimer language really refers to.

Why Compounding Exists in the First Place

Pharmacy compounding is the centuries-old practice of preparing a customized medication for an individual patient when a commercially manufactured product is not appropriate or not available. A patient with a documented allergy to a dye in a brand-name tablet might receive a compounded version without the dye. A pediatric patient might receive a compounded liquid version of a medication that only comes commercially as an adult-sized tablet. A patient prescribed a specific dose strength not commercially produced might receive that exact strength compounded.

The legal framework that governs compounding in the United States lives primarily in two sections of the Federal Food, Drug, and Cosmetic Act: Section 503A and Section 503B. Both sections allow compounding under specific conditions. Both are subject to ongoing FDA oversight. Both produce medications that are not the same regulatory category as FDA-approved finished drugs. Understanding that distinction is the foundation of understanding what you are actually buying when you sign up for a compounded GLP-1 telehealth program.

503A and 503B — The Two Compounding Pathways

A 503A pharmacy is the more traditional pathway. Under Section 503A, a licensed pharmacist or physician can compound a medication for an individual identified patient pursuant to a valid prescription. The compounded preparation must be made from bulk active pharmaceutical ingredients listed on FDA-approved sources. 503A compounding is regulated primarily by State Boards of Pharmacy, with FDA oversight in specific situations. The 503A category includes most independent compounding pharmacies and many telehealth-affiliated pharmacy partners.

A 503B outsourcing facility operates under more stringent rules. 503B facilities can compound medications in larger batches for office-use stocking — for example, supplying a hospital with a batch of a customized injectable. 503B facilities are required to comply with current Good Manufacturing Practice (cGMP) requirements similar to those that apply to drug manufacturers, are inspected directly by the FDA on a regular basis, and must register with the FDA as outsourcing facilities. The 503B pathway is subject to substantially more federal oversight than the 503A pathway.

Some compounded semaglutide and tirzepatide preparations sold through telehealth come from 503A pharmacies. Others come from 503B facilities. Some platforms work with both. The regulatory baseline is different for each, and a patient evaluating a platform can reasonably ask which pathway their medication is being prepared under.

Why Compounded GLP-1 Specifically

Compounded GLP-1 medications became widely available through telehealth during a period when both Ozempic and Wegovy were on the FDA's drug shortage list. FDA regulations historically permit compounding of preparations that contain ingredients from drugs on the shortage list, under specific conditions. As shortage status changed and as the FDA addressed compounding of GLP-1 specifically, the regulatory environment continued to evolve. Enforcement timelines have shifted multiple times, and ongoing litigation continues to shape what compounded GLP-1 preparations are permitted under what conditions.

What this means in practice for a consumer evaluating a platform today: the legal compounding of semaglutide and tirzepatide remains permissible under specific conditions. Those conditions can change. The platform should be transparent about which pharmacy partner is preparing the medication, what regulatory pathway that pharmacy operates under, and how the platform is responding to current FDA guidance. Platforms that hide this information or treat the FDA disclaimer as a perfunctory footnote are demonstrating something about their operational seriousness.

The Three-Entity Model in Modern Telehealth

When a consumer signs up for a compounded GLP-1 telehealth program, three separate entities are involved in delivering the service. The consumer interacts most visibly with the first one — the platform — and may not realize the other two exist as separate parties.

The platform is the technology layer. It operates the website, hosts the intake form, processes payments, manages customer service, and coordinates between the user and the other two entities. The platform itself does not prescribe medications, does not provide clinical care, and typically does not dispense medication. The platform's role is software, logistics, and customer experience. Refills, for example, states this directly in its terms: Refills Health LLC is a technology platform and is not a medical services provider.

The prescribing clinician layer is the medical layer. Independent licensed physicians and nurse practitioners — typically organized through partner medical groups like Beluga Health, Bask Health, or Wasef Health in the case of Refills, or Lion MD in the case of SynergyRx — review the patient's intake, evaluate eligibility against established medical protocols, and write prescriptions when clinically appropriate. The clinician is the only party in the chain who can actually decide whether a patient receives medication. The platform cannot guarantee a prescription, because that decision belongs solely to the evaluating clinician.

The pharmacy layer is the dispensing layer. Once a clinician writes a prescription, that prescription is routed to a licensed pharmacy partner that prepares and ships the medication. The dispensing pharmacy is typically an independent business — operating either as a 503A pharmacy or a 503B outsourcing facility — that has a relationship with the platform but is not owned by the platform. The pharmacy is responsible for the actual preparation of the medication, the quality controls applied to that preparation, and the regulatory compliance of dispensing.

The honest editorial reading of this structure: a compounded GLP-1 telehealth purchase is actually three transactions stitched together with software. Understanding which entity is responsible for what helps a consumer evaluate where the program's strengths and weaknesses live.

What the Intake Process Actually Captures

Telehealth GLP-1 intake forms are generally more thorough than landing-page marketing implies. A typical intake captures medical history (with attention to thyroid disease, pancreatitis history, gallbladder issues, and history of any medullary thyroid carcinoma in the patient or family), current medications (with attention to interactions and contraindications), height and weight (used to calculate BMI), prior weight management history, and treatment goals. Some platforms also request recent lab work or schedule it as part of the program.

The intake is reviewed by a licensed clinician — not an algorithm. That distinction matters. A platform that approves all comers via automated logic is not operating responsibly. A platform that has a clinician review every intake is operating closer to the standard of care that GLP-1 prescribing actually requires.

If the clinician determines that GLP-1 therapy is not clinically appropriate for a particular patient — whether because of a contraindication, an inadequate clinical indication, or any other reason — that patient does not receive a prescription. This is not a failure of the platform; it is the system functioning correctly. Anyone evaluating a platform should view a non-zero rejection rate as a sign of clinical seriousness, not as a customer-experience problem.

What Clinical Trial Data Says — and What It Doesn't

The peer-reviewed clinical trial data referenced across the GLP-1 category was conducted using brand-name finished products, not compounded preparations. The STEP-1 trial of semaglutide 2.4 mg weekly, published in the New England Journal of Medicine in 2021, used Wegovy. The SURMOUNT-1 trial of tirzepatide, published in 2022, used the brand-name finished product. The reported outcomes — approximately 14.9 percent average weight loss with semaglutide at 68 weeks, approximately 22.5 percent with tirzepatide at the highest studied dose at 72 weeks — apply to those finished products under the trial protocols.

Whether compounded semaglutide produces equivalent outcomes is a question the trial data does not directly answer. The active molecule is the same. Bioavailability and pharmacokinetics depend on the specific compounded preparation. Real-world outcomes depend on dose adherence, lifestyle integration, and individual patient response. Anyone evaluating a compounded GLP-1 program should hold the brand-name trial outcomes as a directional reference rather than a guaranteed expectation.

Individual results vary substantially. The trials averaged across hundreds of participants. Within those trials, some participants lost considerably more than the average; others lost less. The same range of variation applies to real-world treatment, and outcomes depend heavily on factors outside any medication: nutrition quality, physical activity, sleep, stress, and behavioral consistency. A medication-only strategy is rarely optimal in either trial settings or real-world settings.

What the FDA Disclaimer Actually Means in Practice

Every compliant compounded GLP-1 telehealth platform displays some version of this disclaimer: compounded medications are dispensed by U.S. pharmacies that are highly regulated and inspected by State Boards of Pharmacy, but the FDA has not evaluated these compounded medications for safety, quality, or efficacy. That language is not a footnote. It is a substantive statement about the regulatory status of what the consumer is purchasing.

What the disclaimer does say: the FDA has not run its own review process on this specific compounded preparation as a finished product. The FDA reviews finished branded drugs through processes like New Drug Applications and post-marketing surveillance. Compounded preparations are not subject to those same processes.

What the disclaimer does not say: that the medication is unsafe, that the compounding pharmacy is unregulated, or that the active molecule has no clinical evidence. State Boards of Pharmacy regulate compounding pharmacies; the active molecule (semaglutide, tirzepatide) has substantial clinical research behind it; and many compounded medications are dispensed safely under appropriate clinical oversight.

The honest reading: the consumer is buying a preparation containing a well-studied active molecule, prepared by a state-regulated pharmacy, prescribed by a licensed clinician, but not the same finished product the FDA reviewed. That distinction is real and important and should inform every consumer evaluation of every compounded GLP-1 platform — including the Refills GLP-1 program and competing platforms in the same category.

Pricing Structures Across the Category

Compounded GLP-1 telehealth pricing typically follows a recurring monthly subscription model. Promotional first-month pricing is common across platforms — entry rates of $99, $149, $159, and $199 appear across the category. Standard recurring rates after the promotional period vary more widely, ranging from roughly $200 to $400 per month, with brand-name medication options pricing substantially higher (often $499 or more for Ozempic, $947 or more for Wegovy or Mounjaro). Annual prepayment discounts are also common, often pricing the equivalent of $150 to $200 per month when paid up front.

The promotional rate is rarely the relevant rate for budgeting. Anyone considering ongoing therapy should plan around the standard recurring rate, then evaluate whether the annual prepayment math is favorable for their situation.

What Patients Should Verify Before Submitting an Intake

A short checklist that applies to evaluating any compounded GLP-1 telehealth platform: who is the platform operator, and where is it incorporated; what medical group employs the prescribing clinicians, and how are clinicians vetted; what dispensing pharmacy fills prescriptions, and is it a 503A or 503B operation; what is the standard monthly price after the promotional period; what is the cancellation process and timing; and how does the platform respond to current FDA guidance on compounded GLP-1.

A platform that answers these questions clearly is operating with appropriate transparency. A platform that obscures any of them is asking the consumer to take more on faith than the consumer should be asked to take. The structural transparency of a platform is itself a meaningful evaluation signal — independent of any individual marketing claim about results.

For a closer look at how one platform's actual structure reads against this framework, our editorial team's Refills GLP-1 review walks through Refills' specific corporate structure, pricing tiers, and disclaimer practices. The safety profile of GLP-1 therapy itself — common side effects, contraindications, and questions to bring to a clinical evaluation — is covered in our companion piece on Refills GLP-1 side effects and safety.

Broader context on the telehealth weight management category lives on our Telehealth Platform Reviews hub, with adjacent coverage of natural and pharmaceutical strategies on the Weight Management hub.

Editorial note: TotalCareMedical.com is an independent health and wellness research publication. We are not a medical practice, do not employ clinicians, and do not provide medical advice. This is an editorial review of Refills as a consumer telehealth platform. Compounded GLP-1 medications dispensed through Refills are not FDA-approved finished drug products. Anyone considering prescription GLP-1 therapy should consult a qualified healthcare provider about eligibility, contraindications, and individual risks. Individual results vary.

Refills is a telehealth platform launched in April 2025 that markets prescription weight management — primarily compounded GLP-1 medications — through an online intake, virtual clinician review, and home-delivery pharmacy fulfillment. The category is crowded. The marketing across the category is, in many cases, structurally similar. What our editorial team does in every telehealth review is the work most reviews skip: trace the corporate structure, audit the actual pricing math beyond the landing-page promo, identify the dispensing pharmacy and partner clinician network, and read the disclaimers carefully enough to understand what the platform is and is not promising.

This review covers what Refills is, who actually prescribes and dispenses, what the program costs across promotional and standard tiers, the FDA compounded-medication context that most reviews bury in a footnote, and a candid take on who this platform realistically fits — and who should look elsewhere.

What Refills Is — and What It Explicitly Says It Is Not

Refills Health LLC is a Delaware-registered telehealth technology company headquartered at 1401 Pennsylvania Avenue, Suite 105, Wilmington, DE 19806. The company is reachable at 888-458-5061 and at support@refills.com. CEO Matt Osborn founded the platform in April 2025 with stated goals around accessibility, simplicity, and transparent pricing.

The structural disclosure on Refills' website is unusually direct, and reading it carefully matters: Refills is not a medical services provider. The assessment provided on the Refills website does not create a clinician–patient relationship between the user and Refills Health. Refills serves as a technology platform that connects users with independent licensed clinicians through partners such as Beluga Health, Bask Health, and Wasef Health. Refills does not manufacture or dispense any medications. All prescribing decisions are made solely at the discretion of the evaluating clinician.

This three-entity structure is common across modern telehealth, and Refills states it more clearly than most peers in the category. We cover what each layer actually does in our companion piece on how compounded semaglutide telehealth works at the platform, prescriber, and pharmacy layers.

The Three-Entity Model in Plain Language

The platform layer — Refills — operates the website, handles the intake form, manages customer service, processes billing, and coordinates between the other two layers. Refills cannot guarantee any individual user receives a prescription, because that determination belongs to the clinician.

The clinician layer is composed of independent licensed providers contracted through Beluga Health, Bask Health, and Wasef Health. These clinicians review the intake submitted through the Refills platform, evaluate eligibility against established medical protocols, and write prescriptions only when they determine treatment is clinically appropriate. If a clinician determines treatment is not appropriate, the user does not receive a prescription. That is a feature of legitimate telehealth, not a flaw.

The pharmacy layer fulfills approved prescriptions. Refills' terms currently identify Perfect Rx Pharmacy in Texas as a dispensing partner and note that additional partners may be added. The terms also permit a patient to direct their prescription to a pharmacy of their own choosing, with the understanding that the patient pays that outside pharmacy directly because the Refills platform price covers in-network fulfillment only.

What Refills Actually Offers

The headline category is GLP-1 weight management. Refills lists access to a Personalized GLP-1 (compounded semaglutide injection) along with brand-name medications including Ozempic, Wegovy, Zepbound, and Saxenda. Whether any individual user receives a brand-name prescription is determined by the evaluating clinician based on clinical appropriateness, availability, and the patient's medical profile.

Refills also operates outside GLP-1. The platform lists categories for Better Intimacy (sildenafil, tadalafil, and brand-name Viagra and Cialis), Daily Health (NAD+, sermorelin, methylene blue), and Hair Growth (oral finasteride, oral minoxidil, and a finasteride-and-minoxidil topical spray). For the purposes of this review, the focus stays on the weight management track because that is where the platform's marketing and the bulk of consumer search demand are concentrated.

The Refills Process from Intake to Delivery

The user-facing flow is straightforward. The patient creates an account on refills.com and completes a health intake covering medical history, current medications, weight history, and treatment goals. A licensed clinician within the partner network reviews the intake — Refills states this typically happens within 24 hours of submission, though timing varies. If the clinician determines GLP-1 therapy is appropriate, a personalized treatment plan is created. The prescription is routed to the dispensing pharmacy. Refills states tracking information is typically issued within two business days of approval and that most orders arrive within three to five business days after prescription approval and pharmacy processing.

Some Refills marketing pages reference free overnight shipping once a label is created. Other pages reference standard three-to-five-day shipping. The discrepancy is worth noting at intake — the consumer should confirm shipping terms at checkout for the specific offer they are entering through.

Pricing — and Why the Landing Page Number Is Not the Number

Refills' most prominent marketing offer is $159 for the first month, framed as an introductory rate. That number is real, and at the introductory price point Refills is aggressively positioned. The number that matters for budgeting, though, is the recurring monthly cost after the promotional period.

An official Refills landing page lists $399 per month for the program after the initial discount. That tier is described as including physician evaluations, follow-ups, unlimited clinician access, monthly prescriptions, a four-week supply of medication, any required blood work, and shipping. Other Refills pages advertise pricing as low as $6 per day when paid for a 12-month plan up front or financed through buy-now-pay-later. That pencils out to roughly $180 per month when averaged across the year — substantially below the $399 standard, comparable to the promotional first month, but requiring full annual prepayment or financing.

The honest budget assumption: plan for a $159 first month, then a recurring monthly spend somewhere in the $180 to $399 range depending on which Refills offer the user enters through and which plan they select. Pricing is subject to change and should be verified at refills.com before any purchase decision. We cover the full pricing math, including what each tier includes and what is not bundled, in our deep-dive on Refills GLP-1 pricing for 2026.

The FDA Compounded Disclaimer Is Substantive — Not Boilerplate

Refills states this directly on its website: compounded medications are dispensed by U.S. pharmacies that are highly regulated and inspected by State Boards of Pharmacy, but the FDA has not evaluated these compounded medications for safety, quality, or efficacy. This is the standard regulatory distinction between compounded preparations and FDA-approved finished drug products, and it is important.

Compounded semaglutide and compounded tirzepatide are prepared by licensed compounding pharmacies — typically operating under FDA Section 503A or 503B designations — using bulk active pharmaceutical ingredients. They are not the same product as Wegovy, Ozempic, Zepbound, or Mounjaro, even when they share an active molecule. The brand-name medications underwent the FDA's full review process for that specific finished formulation. The compounded versions did not. Compounded GLP-1s are also subject to ongoing regulatory and litigation activity, with enforcement timelines that have shifted over time.

None of this means compounded medications are unsafe by definition. Many are dispensed safely under appropriate clinical oversight. It does mean the consumer is not buying the same product they see in a Wegovy commercial, even when the marketing visually suggests an equivalence. That distinction belongs at the front of any honest review of any compounded GLP-1 platform — not in a footnote.

What the Trial Data Actually Shows for the Active Molecules

Compounded semaglutide and brand-name semaglutide share the active molecule. The peer-reviewed clinical trial data referenced across the category — STEP-1 in particular — was conducted using the brand-name finished product, not compounded versions. STEP-1, published in the New England Journal of Medicine in 2021, evaluated semaglutide 2.4 mg weekly in adults with overweight or obesity over 68 weeks. Average weight reduction was approximately 14.9 percent of baseline body weight in the medication arm, compared with 2.4 percent in the placebo arm, when combined with lifestyle intervention.

Tirzepatide trial data references a different molecule — a dual GIP/GLP-1 receptor agonist. SURMOUNT-1, published in 2022, evaluated tirzepatide at three dose levels over 72 weeks in adults with obesity. Average weight reduction at the highest studied dose was approximately 22.5 percent of baseline body weight.

The published trial data is real, peer-reviewed, and meaningful. Two important caveats: the trials were conducted on the brand-name finished products, and individual results vary substantially based on dose tolerance, lifestyle adherence, baseline metabolic profile, and treatment duration. Anyone evaluating outcomes should hold the trial averages as the upper boundary of what well-supervised treatment can achieve under controlled conditions, not as the expected result for any individual patient.

Refund, Cancellation, and What Happens If Something Goes Wrong

Refills' return policy reflects state and federal regulations governing prescription medications. Once a prescription has been dispensed by the pharmacy and handed to a carrier (USPS, FedEx, UPS), all sales on prescription items are final. Returns of dispensed prescription medications are not legally permitted. The user can log into their Refills account before a product is sent to the pharmacy to change address, change payment method, or cancel the subscription.

For non-prescription items, Refills accepts returns of unopened items within 30 days of sale. The customer pays return shipping, COD returns are not accepted, and the item must arrive in its original unopened condition.

If a prescription order arrives damaged or is lost in transit, Refills' patient care team coordinates with the carrier and will reship the order. The customer-service contact for both shipping issues and general support is 888-458-5061 or support@refills.com.

The Consumer Protection Reading — Where the Fine Print Lives

A few items from Refills' terms that any prospective customer should understand before submitting an intake:

Binding arbitration with class-action waiver. Disputes are resolved through individual arbitration; users waive the right to participate in a class action. This is increasingly standard across telehealth and direct-to-consumer health platforms but is worth seeing before signing up rather than after.

Prescription final-sale rule. Once medication is dispensed, refunds are not legally available. The window for cancellation is the period between order placement and the prescription being routed to the pharmacy.

Subscription auto-renewal. The Refills model is recurring. The subscription continues until canceled. Refills states cancellation is available online through the user dashboard at any time, but the consumer is responsible for canceling before the next charge if they want to stop service.

Pharmacy choice. Patients can direct prescriptions to a pharmacy of their choosing, but the platform price covers in-network fulfillment only. Out-of-network pharmacies are paid directly by the patient, which can change the total monthly cost meaningfully depending on the outside pharmacy's pricing.

Who Refills Realistically Fits

The platform fits a specific consumer profile clearly. The introductory $159 price point is among the most aggressive in the category, which makes Refills attractive for someone testing GLP-1 access at low first-month commitment before deciding whether ongoing therapy makes sense. The annual plan averaging around $180 per month is competitive for someone who has already decided GLP-1 is right for them and wants to lock in lower long-term cost in exchange for upfront commitment.

Refills is less ideal for someone who needs strong continuity of in-person care, someone who is uncertain about compounded versus brand-name medications and would benefit from a longer in-person consultation, or someone whose insurance covers brand-name GLP-1 through a traditional primary care or endocrinology referral. For that consumer, working with a primary care physician toward an FDA-approved branded prescription with insurance support is often the better long-term value, even if it requires more time and paperwork upfront.

It is also worth considering how Refills compares against other telehealth GLP-1 platforms operating in the same category. We cover that in our companion Refills vs SynergyRx comparison, and the broader category context lives on our Telehealth Platform Reviews hub. The safety profile of GLP-1 therapy itself — including contraindications, common side effects, and the questions any patient should bring to a clinician evaluation — is covered in our Refills GLP-1 side effects and safety piece.

Final Editorial Take

Refills is a structurally clear telehealth platform. The corporate disclosure is more direct than the category average. The pricing has multiple tiers, and the standard rate is meaningfully higher than the promotional rate, but Refills does not hide the standard rate — it is documented on the platform's own pages. The compounded GLP-1 disclaimer is present on the site and is not buried. The clinician network and dispensing pharmacy are identified, which is more transparency than several competitors offer.

Whether Refills is the right choice for any individual user is a clinical and financial question that belongs between the user and a licensed healthcare provider. What this review can say with confidence is that Refills' marketing claims line up with what the company's own terms and policies state, the pricing is real if more layered than the landing page implies, and the FDA compounded-medication context is something every prospective patient should understand before submitting an intake. The platform is what it presents itself as. Whether the platform's offering fits the patient is the patient's decision to make in consultation with a clinician.

For broader weight management context — including evidence-based natural strategies and the full editorial framework we apply to GLP-1 telehealth — see our Weight Management hub.